TABLE 1.
Demographic characteristics of patients.
| Orchiectomy n = 19 | Chemotherapy n = 35 | BMT n = 11 | |
|---|---|---|---|
| Median age (min–max) | 29 (20–44) | 29 (18–45) | 25 (18–37) |
| BMI, kg/m2, median (IQR) | 25.9 (22.7–31) | 25.9 (24.3–29.1) | 25.3 (24.2–29.7) |
| Smoking (%) | |||
| Never | 12 (63.1) | 20 (57.1) | 7 (63.6) |
| Former | 2 (10.5) | 10 (28.6) | 2 (18.1) |
| Current | 5 (26.3) | 5 (14.3) | 2 (18.1) |
| Drinking frequency (%) | |||
| None | 10 (52.6) | 18 (51.4) | 6 (54.5) |
| Light | 4 (21.1) | 9 (25.7) | 3 (27.3) |
| Moderate | 5 (26.3) | 3 (8.6) | 2 (18.2) |
| Heavy | 0 | 2 (5.7) | 0 |
| Very heavy | 0 | 3 (8.6) | 0 |
| Physical activity (%) | |||
| None | 18 (94.7) | 31 (88.6) | 11 (100) |
| Light (1.1–2.9 METs) | 0 | 0 | 0 |
| Moderate (3–5.9 MET) | 1 (5.2) | 3 (8.6) | 0 |
| Vigorous (>6 METs) | 0 | 1 (2.9) | 0 |
| Histology | |||
| Seminoma | 8 (42.1) | 14 (40) | 1 (9) |
| Nonseminoma | 11 (57.8) | 21 (60) | 10 (90.9) |
| Clinical stage | |||
| I | 19 (100) | 6 (17.1) | 0 |
| II | 0 | 12 (34.2) | 0 |
| III | 0 | 17 (48.5) | 11 (100) |
| Chemotherapy regimen | |||
| BEP a 1 | 0 | 5 (14.2) | 0 |
| BEP ≥3 | 0 | 10 (28.5) | 3 (27.2) |
| BEP 4 | 0 | 11 (31.4) | 0 |
| BEP >4 | 0 | 0 | 0 |
| TIP b | 0 | 7 (20) | 6 (54.5) |
| ICE c | 0 | 2 (5.7) | 0 |
| VIP d | 0 | 0 | 2 (18.1) |
| Retroperitoneal radiotherapy | |||
| Yes | 0 | 6 (17.1) | 3 (27.3) |
| No | 19 (100) | 29 (82.9) | 8 (72.2) |
| Retroperitoneal lymph node dissection | |||
| Yes | 0 | 14 (40) | 3 (27.3) |
| No | 19 (100) | 21 (60) | 8 (72.7) |
| Median testosterone (ng/mL) value (IQR) | 3.87 (3.17–4.52) | 3.71 (2.87–4.36) | 3.36 (2.74–3.64) |
| Median time on surveillance (months) (min–max) | 50 (4–167) | 59 (12–213) | 99 (40–210) |
a
Bleomycin, etoposide, and cisplatin.
b
Paclitaxel, ifosfamide, and cisplatin.
c
Ifosfamide, carboplatin, and etoposide.
d
Cisplatin, etoposide, and ifosfamide.